Karus CEO highlights niche indications for oncology innovation

Karus Therapeutics CEO, Simon Kerry, talks to Scrip senior writer, Lucie Ellis, during the recent BIO-Europe® partnering meeting about the company’s cancer-focused pipeline and where its products will sit within the crowded oncology market space. Kerry highlights Karus' strategy of targeting niche cancer indications and outlines how the smaller biotech will compete with big pharma businesses active in oncology drug development.